Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Agrylin (anagrelide)
i
Other names:
SPD422, BL 4162A, BMY 2653801, KRN654, BL4162A, BMY2653801, KRN 654, SPD 422, BL-4162A, BMY-2653801, KRN-654, SPD-422
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Takeda
Drug class:
Phospholipase A2 inhibitor, PDE3 inhibitor
Related drugs:
‹
hydroxychloroquine (7)
hydroxychloroquine MDT (0)
icosapent ethyl (0)
ibudilast (0)
hydroxychloroquine (7)
hydroxychloroquine MDT (0)
icosapent ethyl (0)
ibudilast (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PDE3A overexpression
Acute Myelogenous Leukemia
PDE3A overexpression
Acute Myelogenous Leukemia
idarubicin hydrochloride + anagrelide
Sensitive: D – Preclinical
idarubicin hydrochloride + anagrelide
Sensitive
:
D
idarubicin hydrochloride + anagrelide
Sensitive: D – Preclinical
idarubicin hydrochloride + anagrelide
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login